| Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L) 1 monotherapy: a multicentre, retrospective, cohort study IP da Silva, T Ahmed, ILM Reijers, AM Weppler, AB Warner, JR Patrinely, ... The Lancet Oncology 22 (6), 836-847, 2021 | 133 | 2021 |
| Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial AM Hong, GB Fogarty, K Dolven-Jacobsen, BH Burmeister, SN Lo, ... Journal of clinical oncology 37 (33), 3132-3141, 2019 | 105 | 2019 |
| Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients TN Gide, IP Silva, C Quek, T Ahmed, AM Menzies, MS Carlino, RPM Saw, ... Oncoimmunology 9 (1), 1659093, 2020 | 69 | 2020 |
| Clinical models to define response and survival with anti–PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma I Pires da Silva, T Ahmed, JL McQuade, CA Nebhan, JJ Park, JM Versluis, ... Journal of Clinical Oncology 40 (10), 1068-1080, 2022 | 52 | 2022 |
| Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+ PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. I Pires Da Silva, T Ahmed, S Lo, ILM Reijers, A Weppler, A Betof Warner, ... Journal of Clinical Oncology 38 (15_suppl), 10005-10005, 2020 | 37 | 2020 |
| Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas MA El Sharouni, T Ahmed, AHR Varey, SG Elias, AJ Witkamp, ... Journal of Clinical Oncology 39 (11), 1243-1252, 2021 | 31 | 2021 |
| Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor MA El Sharouni, MD Stodell, T Ahmed, KPM Suijkerbuijk, AE Cust, ... Annals of Oncology 32 (3), 375-383, 2021 | 29 | 2021 |
| Histological regression in melanoma: impact on sentinel lymph node status and survival K Aivazian, T Ahmed, MA El Sharouni, JR Stretch, RPM Saw, AJ Spillane, ... Modern Pathology 34 (11), 1999-2008, 2021 | 27 | 2021 |
| Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab KJ Nahar, RV Rawson, T Ahmed, S Tattersall, N Sandanayake, CJ Kiely, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 27 | 2020 |
| Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy GH Attrill, CN Owen, T Ahmed, IA Vergara, AJ Colebatch, JW Conway, ... Journal for Immunotherapy of Cancer 10 (6), 2022 | 26 | 2022 |
| Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma P Bhave, T Ahmed, SN Lo, A Shoushtari, A Zaremba, JM Versluis, ... Journal for immunotherapy of cancer 10 (7), 2022 | 24 | 2022 |
| Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large … MA El Sharouni, AHR Varey, AJ Witkamp, T Ahmed, V Sigurdsson, ... British Journal of Dermatology 185 (2), 412-418, 2021 | 24 | 2021 |
| Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites JW Conway, RV Rawson, S Lo, T Ahmed, IA Vergara, TN Gide, GH Attrill, ... Journal for Immunotherapy of Cancer 10 (9), 2022 | 22 | 2022 |
| Clinical and molecular heterogeneity in patients with innate resistance to anti-pd-1+/− anti-ctla-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets TN Gide, I Pires da Silva, C Quek, PM Ferguson, M Batten, P Shang, ... Cancers 13 (13), 3186, 2021 | 13 | 2021 |
| Predicting recurrence in patients with sentinel node‐negative melanoma: validation of the EORTC nomogram using population‐based data MA El Sharouni, T Ahmed, AJ Witkamp, V Sigurdsson, CH van Gils, ... British Journal of Surgery 108 (5), 550-553, 2021 | 11 | 2021 |
| Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma IP da Silva, D Zakria, T Ahmed, C Trojanello, F Dimitriou, C Allayous, ... Journal for Immunotherapy of Cancer 10 (7), 2022 | 9 | 2022 |
| External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma NA Ipenburg, OE Nieweg, T Ahmed, R van Doorn, RA Scolyer, GV Long, ... Journal of British Surgery 106 (10), 1319-1326, 2019 | 8 | 2019 |
| Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma I Silva, A Tasker, C Quek, R Rawson, SY Lim, K Wang, J Conway, ... Cancer Research 79 (13_Supplement), 975-975, 2019 | 6 | 2019 |
| Primary dermal melanoma: clinical behaviour, prognosis and treatment CG Harris, S Lo, T Ahmed, RA Scolyer, PM Ferguson, RZ Karim, TK Lam, ... European Journal of Surgical Oncology 46 (11), 2131-2139, 2020 | 5 | 2020 |
| Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan SN Lo, AM Hong, LE Haydu, T Ahmed, EJ Paton, V Steel, G Hruby, A Tran, ... Trials 20, 1-13, 2019 | 5 | 2019 |
